Skip to main content
Premium Trial:

Request an Annual Quote

Incyte, Eli Lilly Expand Collaboration

Premium

Incyte Genomics of Palo Alto, Calif., and Eli Lilly of Indianapolis have expanded an agreement to collaborate on accelerating the development of therapeutic proteins. Under the terms of the new agreement, Eli Lilly and Incyte will focus on identifying and selecting secreted molecules that are strong candidates for therapeutic protein development. Eli Lilly will also obtain options to license multiple therapeutic protein patents from Incyte.

Financial terms of the deal were not disclosed.

Over the last three years, Lilly has used Incyte’s LifeSeq Gold database in its drug discovery and development efforts.

Incyte has more than 500 issued and allowed patents on full-length genes, including 134 issued patents on therapeutic proteins.

Filed under

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.